0001104659-23-112178.txt : 20231027 0001104659-23-112178.hdr.sgml : 20231027 20231027161531 ACCESSION NUMBER: 0001104659-23-112178 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20231025 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231027 DATE AS OF CHANGE: 20231027 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Sorrento Therapeutics, Inc. CENTRAL INDEX KEY: 0000850261 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 330344842 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36150 FILM NUMBER: 231355701 BUSINESS ADDRESS: STREET 1: 4955 DIRECTORS PLACE CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-203-4100 MAIL ADDRESS: STREET 1: 4955 DIRECTORS PLACE CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: QUIKBYTE SOFTWARE INC DATE OF NAME CHANGE: 19920703 8-K 1 tm2329328d1_8k.htm FORM 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): October 25, 2023

SORRENTO THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware

001-36150

33-0344842

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

4955 Directors Place

San Diego, CA 92121

(Address of Principal Executive Offices) (Zip Code)

Registrant’s telephone number, including area code: (858) 203-4100

N/A

(Former Name, or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities Registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
Common Stock, $0.0001 par value		SRNE		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On October 25, 2023, Tammy Reilly notified Sorrento Therapeutics, Inc. (the “Company”) that she was resigning from the Board of Directors of the Company (the “Board”), effective immediately. Ms. Reilly informed the Company that her resignation was due to concerns regarding the Company’s Chief Restructuring Officer’s continued lack of communication with the Board on decisions made and the general operating of the Company and changes in the Company’s directors’ and officers’ insurance policy without Board input. A copy of Ms. Reilly’s letter of resignation is attached hereto as Exhibit 17.1.

The Company has provided Ms. Reilly with a copy of the disclosures in this Form 8-K and the opportunity to furnish the Company with a letter addressed to the Company stating whether she agrees with the statements made by the Company in response to this Item 5.02 and if not, stating the respects in which she does not agree. Upon the receipt of any such letter from Ms. Reilly, the Company will file any such letter as an exhibit to an amendment to this Form 8-K, no later than two business days after it is received.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

17.1	Ms. Reilly Resignation Letter, dated October 25, 2023.

104	Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	SORRENTO THERAPEUTICS, INC.

Date: October 27, 2023	By:	/s/ Henry Ji, Ph.D.
		Name: Henry Ji, Ph.D.
		Title: Chief Executive Officer

EX-17.1 2 tm2329328d1_ex17-1.htm EXHIBIT 17.1

Exhibit 17.1

From: Tammy Reilly <[…***…]@[…***…].com>

Sent: Wednesday, October 25, 2023 11:46 AM

To: Henry Ji <[…***…]@sorrentotherapeutics.com>

Subject: BOD Resignation

Good morning,

It is with dismay that I inform you of my decision to resign from the Board of Directors for Sorrento Therapeutics effective immediately.

I have become increasingly concerned at the CRO’s continued lack of communication with the BOD on decisions made and general operating of the company thus, resulting in unilateral decision making by the CRO. Further to this, the decision by the CRO without BOD input to ineffectively and irresponsibility act regarding changes in the D&O policy reinforced my decision.

Sincerely,

Tammy Reilly

EX-101.SCH 3 srne-20231025.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 srne-20231025_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 srne-20231025_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT

Cover	Oct. 25, 2023
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Oct. 25, 2023
Entity File Number	001-36150
Entity Registrant Name	SORRENTO THERAPEUTICS, INC.
Entity Central Index Key	0000850261
Entity Tax Identification Number	33-0344842
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	4955 Directors Place
Entity Address, City or Town	San Diego
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92121
City Area Code	858
Local Phone Number	203-4100
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, $0.0001 par value
Trading Symbol	SRNE
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false

XML 7 tm2329328d1_8k_htm.xml IDEA: XBRL DOCUMENT 0000850261 2023-10-25 2023-10-25 iso4217:USD shares iso4217:USD shares 0000850261 false 8-K 2023-10-25 SORRENTO THERAPEUTICS, INC. DE 001-36150 33-0344842 4955 Directors Place San Diego CA 92121 858 203-4100 false false false false Common Stock, $0.0001 par value SRNE NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://sorrentotherapeutics.com/role/Cover Cover Cover 1 false false All Reports Book All Reports srne-20231025.xsd srne-20231025_lab.xml srne-20231025_pre.xml tm2329328d1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm2329328d1_8k.htm": { "nsprefix": "srne", "nsuri": "http://sorrentotherapeutics.com/20231025", "dts": { "schema": { "local": [ "srne-20231025.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "srne-20231025_lab.xml" ] }, "presentationLink": { "local": [ "srne-20231025_pre.xml" ] }, "inline": { "local": [ "tm2329328d1_8k.htm" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://sorrentotherapeutics.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-10-25", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2329328d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-10-25", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2329328d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 14 0001104659-23-112178-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-112178-xbrl.zip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end